MarginsXMarginsX
Home › Markets › Health Care › SCNI

Scinai Immunotherapeutics Ltd. (SCNI)

SCNI trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.4041
+1.02% on the day
Market cap
$1.1M
Nano cap
Revenue · 2025
$1.3M
+99.2% on 2024
Net income · 2025
-$8.3M
-633.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1611747/000121390026038011/0001213900-26-038011-index.htm. Net income: SEC 20-F (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerSCNI on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryIsrael
IPO year2015
SEC CIK0001611747
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inIsrael

Financials · 2025

LineValue
Revenue$1.3M
Net income-$8.3M
Operating income-$7.5M
Net margin-633.6%
Operating margin-575.3%
Revenue growth+99.2%
Cash$1.7M
Total assets$11.6M
P/E (computed)Net income was not positive
P/S (computed)0.8×

Warning signs

Cash runway
3.3 months
$1.7M cash at December 31, 2025
Share count, 1 year
+306.6%
2024-12-31 to 2025-12-31 · +10460.8% over 3 years
Going-concern doubt
Yes
20-F filed April 1, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"Accordingly, there is substantial doubt about our ability to continue as a going concern."
20-F 2026-04-01
Cash and burn$1.7M cash; operating cash flow -$1.5M a quarter.Report 2025-12-31
Shares outstandingNo cover-page share count in XBRLCover page 2025-12-31
Reverse splits, 3 years2; latest 1-for-10 on 2026-08-21Source 2026-08-21
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-10-28
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorZiv Haft Certified Public Accountants (Isr.), Tel Aviv, IsraelPCAOB Form AP 2026-04-30
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
$1.3M-$8.3M-$6.0M$1.7MNo debt tags$1.3M20-F 2026-04-01
Q1 2023
2023-03-31
Not filed-$3.5M-$3.1M$10.8MNo debt tagsNeeds four quarters10-Q 2023-05-15
Q1 2022
2022-03-31
Not filed-$2.5M-$1.1M$15.4MNo debt tagsNeeds four quarters10-Q 2023-05-15

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
PROSPECTUS
424B32026-11-10
Latest annual report
ANNUAL REPORT
20-F2026-04-01
Latest quarterly / interim
REPORT OF FOREIGN PRIVATE ISSUER
6-K2026-11-09
Latest current report
CURRENT REPORT
8-K2023-06-08

Source: SEC EDGAR submissions feed, 498 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-9.3%
1 month-67.5%
3 months-83.3%
Year to date-94.4%
1 year-96.0%
From 52-week high-96.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
SLXNSilexion Therapeutics Corp$1.76-11.11%$1.1M
CLDICalidi Biotherapeutics Inc.$0.6023-3.15%$2.2M
VIVSVivoSim Labs Inc.$0.1237-2.68%$2.5M
CELZCreative Medical Technology Holdings Inc.$0.5201-1.51%$4.0M
LIMNLiminatus Pharma Inc.$2.97-0.67%$4.0M
CRISCuris Inc.$0.4358-2.07%$4.1M
BTTCBlack Titan Corporation$0.2873-9.20%$4.3M
AIMAIM ImmunoTech Inc.$0.1310-8.77%$5.2M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier